Carmine Bryce D.

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
16
Insider Sells Sum
$2.67M

Insider Activity of Carmine Bryce D.

The largest sale of all time was on 2011-12-12 and amounted to 5787 shares of Eli Lilly and Company for $226,272.

Biography of Carmine Bryce D.

No biography is available at this moment.

2011-12-12SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
5,787
0.0005%
$39.10$226,272+9.25%
2011-11-11SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
5,700
0.0005%
$37.55$214,035+10.44%
2011-10-11SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
5,700
0.0005%
$38.10$217,170+10.58%
2011-09-12SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
5,700
0.0005%
$35.91$204,687+13.75%
2011-08-11SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
5,700
0.0005%
$33.94$193,458+14.74%
2011-07-11SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
5,700
0.0005%
$37.39$213,123+9.17%
2011-06-13SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
5,700
0.0005%
$37.25$212,325+7.84%
2011-05-11SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
5,700
0.0005%
$38.21$217,797+1.12%
2011-04-11SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
5,700
0.0005%
$35.76$203,832+8.42%
2011-02-16SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
3,100
0.0003%
$34.49$106,919+10.22%
2011-01-14SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
3,100
0.0003%
$34.87$108,097+10.28%
2010-12-16SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
3,100
0.0003%
$35.10$108,810+8.47%
2010-11-16SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
3,100
0.0003%
$34.43$106,733+8.99%
2010-10-15SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
3,100
0.0003%
$37.65$116,715-2.46%
2010-09-16SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
3,100
0.0003%
$35.55$110,205+2.02%
2010-08-16SaleEli Lilly and Company
LLY
EVP and Pres, Lilly Bio-Meds
3,100
0.0003%
$35.33$109,523+1.04%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.